Fox Chase Cancer Center

Latest from Fox Chase Cancer Center


Axitinib/Pembrolizumab Combination Improves Survival in Metastatic RCC, But Only Marginally

October 17, 2021

A real-world survival analysis showed that patients with metastatic RCC treated with axitinib plus pembrolizumab did not experience significantly improved survival outcomes compared with patients treated with ipilimumab plus nivolumab.